Rx Risk Management Guidances: FDA To Seek Input Through Public Meetings
Executive Summary
FDA will hold a series of public meetings on risk assessment, risk management and pharmacovigilance over the next 12 months in preparation for drafting guidances on those topics
You may also be interested in...
FDA Rx Risk Assessment Guidance May Detail Lab Test Parameters
FDA's risk assessment working group is considering developing specific recommendations on which lab test results could signal safety problems for drugs under review
FDA Rx Risk Assessment Guidance May Detail Lab Test Parameters
FDA's risk assessment working group is considering developing specific recommendations on which lab test results could signal safety problems for drugs under review
FDA Plans Three Risk Management-Related Guidances Under PDUFA III
FDA's PDUFA III implementation plan will likely include three separate guidances to cover risk assessment, pharmacovigilance and risk management